Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Aequus Pharmaceuticals Inc V.AQS

Alternate Symbol(s):  AQSZF

Aequus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company focused on developing, advancing, and promoting differentiated products. The Company is engaged in the sale and marketing of several commercial products in ophthalmology and transplant. Its pipeline products include Evolve Intensive Gel, Evolve Daily Intensive, SCOPE Portfolio, Zimed PF and REV-0100 / ReVision. Evolve Intensive Gel and Evolve Daily Intensive contains lubricating eye drops intended for use in the relief of discomfort that arises from dry eye sensations, including dryness, soreness, feelings of grit, and irritation. Zimed PF is a preservative-free multi-dose Bimatoprost for glaucoma patients in Canada. REV-0100 is in preclinical development as a treatment for Stargardt disease. It plans to build on its Canadian commercial platform through the launch of additional products that are either created internally or brought in through an acquisition or license.


TSXV:AQS - Post by User

Bullboard Posts
Comment by stockwatch99on Apr 10, 2019 2:28am
53 Views
Post# 29605298

RE:RE:RE:RE:RE:RE:Links...interesting reading...

RE:RE:RE:RE:RE:RE:Links...interesting reading...Lol, you are very funny. After you latest rant and "all the way down" prediction, the share price was moving up 15% from Wednesday to Monday, from 0.17CAD to 0.195CAD. Where were you then? Quiet in your little corner! Now the share price drops to 0.18CAD with lower volume and you're back ranting. Transparent bashing this is called.

Furthermore, it is irrelevant what the share price is doing during the next 1-2 weeks. The important part is what happens after financing closes and AQS will start issuing a news flow with plenty of interesting news. News about revenue growth, the Trokendi study start, the new ophthalmology product, more Zepto deals, the cannabis product plans, etc.

Of course, you have no clue about all these things but hey, who in the Internet needs any knowledge when you just can have an anonymous opinion ... blah blah blah ...
Bullboard Posts